Calidi Biotherapeutics 株価情報 (AMEX: CLDI)

最新ニュース Calidi Biotherapeutics (AMEX:CLDI) 株価情報

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Morgan Stanley analyst Benjamin Swinburne maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Equal-Weight and raises the price target from $385 to $415.

Price Target

Analyst Ratings

CHTR

Morgan Stanley Maintains Equal-Weight on Charter Communications, Raises Price Target to $415

Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) reported quarterly earnings of $0.79 per share. This is a 61.22 percent increase over earnings of $0.49 per share from the same period last year. The company reported $9.58 billion in sales this quarter. This is a 8.74 percent decrease over sales of $10.50 billion the same period last year.

Earnings

Fomento Economico Mexicano S.A.B. De C.V.

Fomento Economico Q1 Net majority income per FEMSA ADS $0.79 Up From $0.49 YoY, Total Revenues $9.58B Down From $10.50B YoY

ONDS

Ondas Holdings Secures $3.4M Order For Iron Drone Raider Counter-UAS System From European Defense Contractor For Governmental End Client

Macro Economic Events

Rumors

Global

Economics

Watching Domino's Pizza; Shares Lower In Premarket, During Conf Call, Exec Reportedly Says Delivery Business Impacted By Macro Pressures On Lower-Income Consumer

Barclays analyst Adrienne Yih maintains Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) with a Equal-Weight and lowers the price target from $7 to $5.

Barclays Maintains Equal-Weight on Hanesbrands, Lowers Price Target to $5

Offerings

Old Republic Announces Prospectus Supplement Related To Offer By Sales Of Up To 2,829,509 Shares By At $1.00/Share

Barclays analyst Paul Kearney maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Underweight and lowers the price target from $25 to $21.

GIII

Barclays Maintains Underweight on G-III Apparel Group, Lowers Price Target to $21

Morgan Stanley analyst Vincent Andrews maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $125 to $115.

Morgan Stanley Maintains Overweight on Eastman Chemical, Lowers Price Target to $115

Citizens Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZWI#NASDAQ">CZWI</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.27 by 18.52 percent. This is a 17.95 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $14.19 million which beat the analyst consensus estimate of $11.60 million by 22.30 percent. This is a 6.47 percent decrease over sales of $15.17 million the same period last year.

Earnings Beats

CZWI

Citizens Community Q1 Adj. EPS $0.32 Beats $0.27 Estimate, Sales $14.19M Beat $11.60M Estimate

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/HON/earnings">opening bell on Tuesday, April 29.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $2.21 per share, down from $2.25 per share in the year-ago period. Honeywell projects quarterly revenue of $9.6 billion, compared to $9.11 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 14, Citigroup analyst Andrew Kaplowitz maintained Honeywell with a Buy rating. He also lowered the price target from $253 to $229.
With the recent buzz around Honeywell, some investors may be eyeing potential gains from the company's dividends too. Currently, Honeywell offers an annual dividend yield of 2.27%. That&#8217;s a quarterly dividend of $1.13 per share ($4.52 a year).
To figure out how to earn $500 monthly from Honeywell, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Honeywell's $4.52 dividend: $6,000 / $4.52 = 1,327 shares.
So, an investor would need to own approximately $264,285 worth of Honeywell, or 1,327 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $4.52 = 265 shares, or $52,777 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Price Action: Shares of Honeywell fell by 0.8% to close at $199.16 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Trading Ideas

How To Earn $500 A Month From Honeywell International Stock Ahead Of Q1 Earnings

Contracts

Hudbay Minerals Signs Agreement With The Mosakahiken Cree Nation On Exploration Activities In Their Traditional And Ancestral Territory, Including At Hudbay's Talbot Deposit South Of Snow Lake, Manitoba

As Big Tech steps onto the earnings stage this week, tariff worries swirl, but the AI Revolution isn't slowing down. Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) are all set to report and Wedbush Securities&#8217; analyst Dan Ives says the setup is more bullish than bearish.
<h2 class="wp-block-heading">Week Ahead: Big Tech&#8217;s Demand Trends In Focus</h2>
&#8220;This is a major week ahead for the markets and tech world,&#8221; Ives said as Wall Street braces for updates on cloud spending, digital ads, and enterprise AI budgets. Despite tariff noise dominating headlines, the Street is &#8220;laser-focused&#8221; on Big Tech demand trends &#8211; and Ives expects &#8220;generally very strong results&#8221; across the board.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44977897/exclusive-nvidia-alphabet-microsoft-amazon-meta-now-in-the-bargain-bin-after-being-heavily-sold-off-says-expert" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Nvidia, Alphabet, Microsoft, Amazon, Meta &#8211; Now In The Bargain Bin After Being &#8216;Heavily Sold Off&#8217;, Says Expert</a>
Microsoft and Amazon are riding a cloud spending surge, while Meta benefits from a digital advertising rebound. Even with the tariff overhang, Ives reports that CIOs and IT leaders have &#8220;very firm Cap-Ex intentions for 2025&#8221; in place, with AI deployments ramping across the enterprise landscape.
About 15% of IT budgets are now AI-driven — and those dollars are being fiercely defended.
<h2 class="wp-block-heading">Apple Could Take A 15-20% Hit</h2>
But for Apple, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44788262/apples-margins-catch-a-break-but-road-ahead-still-looks-bumpy">the tariff story looms large</a>. While the Cupertino-based company is expected to post solid results, the real question is what happens if the China tariffs stick.
Ives warns that in a worst-case scenario, Apple's 2025–26 numbers could take a 15–20% hit, although a quicker resolution could limit the damage to just 2–5%.
Still, Wedbush remains firmly in Apple&#8217;s corner, pointing to its &#8220;1.5 billion iPhone and 2.4 billion iOS installed base and massive Services business&#8221; as critical anchors for weathering the tariff storm.
Bottom line? Big Tech's earnings could serve as a significant &#8220;confidence booster&#8221; if investors can keep their eyes on the long-term AI prize and not get swept away by tariff turbulence.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44977897/exclusive-nvidia-alphabet-microsoft-amazon-meta-now-in-the-bargain-bin-after-being-heavily-sold-off-says-expert">S&amp;P 500, Magnificent 7 Hit Resistance: Analyst Warns Of More Pain Before Gain</a></li>
</ul>
Photo: Shutterstock

Previews

Tech

AAPL

AMZN

MSFT

Microsoft, Meta, Amazon, Apple Gear Up For 'AI Revolution' Week As Tariff Storm Brews

-&nbsp; Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working
-&nbsp; ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option
-&nbsp; ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs
NEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following treatment with Pluvicto. Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed radiotherapy radiolabeled with the beta-particle emitter, Lutetitium-177 (Lu-177) is approved for patients with metastatic castration-resistant prostate cancer. Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024.

ATNM

Actinium Pharma Announces ATNM-400 Preclinical Data Highlighting Sustained Tumor Control and Safety for Prostate Cancer Patients Post-Pluvicto

POET Technologies Inc. ("POET" or the "Corporation") (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/PTK#TSXV">PTK</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks today announces its intention to complete a non-brokered public offering of 5,000,000 units of the Corporation (the "Units") at a price of US$5.00 per Unit (the "Issue Price") for aggregate gross proceeds to the Corporation of US$25 million (the "Offering"). Each Unit will be comprised of one common share of the Corporation (each, a "Common Share") and one common share purchase warrant of the Corporation (each, a "Warrant"), with each Warrant being exercisable to acquire one Common Share at a price of C$8.32 for a period of five years from the date of issuance.
The Issue Price represents a premium of approximately 21.8% over the closing price of the Common Shares on the TSX Venture Exchange on Friday, April 25, 2025. The Corporation anticipates using the net proceeds of the Offering for working capital and general corporate purposes.

POET

TSXV:PTK

POET Technologies Announces $25M Offering Of 5M Units At A Price Of $5/Unit

CVLT

Commvault Wins GovRAMP Authorization Status For Commvault Cloud

CRWD

Commvault Expanded Partnership With CrowdStrike To Delver Unifed Set Of Services

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today is proud to announce a landmark achievement: our AmpliTech Inc. division has secured its highest value purchase order in history with the receipt this past Friday of a combined $2 million purchase orders for our proprietary Low Noise Amplifiers from a U.S. Fortune 500 company.
This major win for our core low noise amplifiers division marks the culmination of the most prolific four-month order period in our corporate history, driving our total backlog to nearly $20 million, all slated for delivery within Fiscal Year 2025.

AMPG

AmpliTech Group Division AmpliTech Inc. Receives Division Purchase Orders Of $2M From A Fortune 500 Company; Total Backlog To Nearly $20M, All Slated For Delivery Within Fiscal Year 2025

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday.
Shares of Eagle Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) fell sharply in today's pre-market trading after the company released financial <a href="https://www.benzinga.com/quote/efsi">results for the first quarter</a>.
Eagle Financial Services reported quarterly earnings of 62 cents per share, down from 72 cents per share in the year-ago period.
Eagle Financial Services shares dipped 5.8% to $30.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares dipped 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) declined 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) shares fell 8.3% to $7.03 in pre-market trading.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) tumbled 6.8% to $6.81 in pre-market trading.</li>
<li>Magnera Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) dipped 6.8% to $13.41 in pre-market trading. Magnera is expected to report second quarter results on May 7.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) fell 6.4% to $9.13 in pre-market trading.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 2.8% to $13.35 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) slipped 2.2% to $11.85 in pre-market trading. Delcath Systems will host a conference call on May 8 to discuss results for its first quarter.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.5% to $109.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a></li>
</ul>
Photo via Shutterstock

ANNA

BLCO

DCTH

EFSI

HLMN

MAGN

NVDA

OMER

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada.
The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval.

Biotech

General

ACOG

Alpha Cognition To Present ZUNVEYL Clinical Data At 2025 AAIC

Elon Musk's space-based internet service provider, Starlink, could reportedly face delays in its plans to expand into India due to regulatory requirements.
What Happened: India's telecom minister, Jyotiraditya Scindia, reiterated that Musk's company must comply with stringent local regulations if it plans to operate in the country, <a href="https://www.rcrwireless.com/20250425/5g/starlink-india-telecom-minister">according</a> to RCR Wireless on Friday.
"The process is ongoing. The minute they meet all conditions — including setting up gateways in India and registering user terminals locally — we are ready to issue the license," Scindia said.
SpaceX did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
However, Starlink must go through a significant amount of red tape to get its license in India, as the process involves multiple government agencies like the Department of Telecommunications (DoT), the Telecom Regulatory Authority of India (TRAI), and the Indian National Space Promotion and Authorization Center (IN-SPACe).
"It's not only related to DoT, but also to internal security — gateways have to be in India, any user terminal has to be registered in India…the minute they check all the boxes, which I also hope will be soon, the license should be given," Scindia said, reiterating the importance of domestic gateways and user terminals.
Why It Matters: The news comes in as Starlink just added 13 more low-earth orbit satellites to its constellation aboard SpaceX's Falcon 9 rocket. Starlink has a healthy lead in the space-based internet race with its constellation boasting <a href="https://www.benzinga.com/general/space/25/04/44806935/spacex-launches-27th-falcon-9-rocket-from-florida-adds-27-starlink-satellites-to-orbit">over 7,000 satellites</a> and operating in more than 100 countries.
Starlink also recently<a href="https://www.benzinga.com/25/03/44268506/elon-musk-led-spacex-inks-agreements-with-indias-top-telecom-providers-expands-addressable-market-by-over-850-million-users"> signed an agreement</a> with two of India's major telecom providers, Bharati Airtel, as well as billionaire Mukesh Ambani's Jio Platforms Ltd., to provide satellite internet services in the country.&nbsp;
Musk has been eyeing India for a while, and spoke with Indian Prime Minister Narendra Modi recently, where the <a href="https://www.benzinga.com/general/space/25/04/44882314/tesla-ceo-elon-musk-indian-pm-modi-discuss-deeper-tech-ties-amid-model-y-test-run-in-mumbai">two reportedly discussed</a> ‘immense potential' for collaboration in ‘technology and innovation,' among other things.
On the other hand, Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper, Starlink's closest competitor, <a href="https://www.benzinga.com/general/space/25/04/44977151/jeff-bezos-space-internet-ambitions-falter-as-amazons-project-kuiper-struggles-to-increase-satellite-production-amid-launch-delays">faces significant challenges </a>in deploying its low Earth orbit satellites.
Elsewhere, SpaceX is among the ‘frontrunners' to build U.S. President Donald Trump's <a href="https://docs.google.com/document/d/1IAGucq2_2ZpFiUaXA_9zTDUHAjJYXHUzs3VLrbjGGKw/edit">Golden Dome Missile Defense System</a>, along with Peter Thiel's Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45029648/tesla-stock-skyrockets-20-following-elon-musks-return-and-shift-from-doge">Tesla Stock Skyrockets 20% Following Elon Musk&#8217;s Return and Shift From DOGE</a></li>
</ul>
Image Via Shutterstock

SPACE

PLTR

Elon Musk's India Ambitions Face Regulatory Hurdles Amid Uncertainty Around Starlink License: Report

Press Releases

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Financing

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Management

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

Health Care

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting

MTEM

Abpro Hldgs

ABVC BioPharma

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

IN8bio

Kala Bio

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

BiomX

Polyrizon

Portage Biotech

SAB Biotherapeutics

Synlogic

Unity Biotechnology

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

オラクル・コーポレーション (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) の株価は、同社が<a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google">第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。</a>
オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>）のGoogle Cloudと提携することも発表しました。
プレマーケット取引でオラクルの株は前場で135.00ドルに急騰しました。
以下は、プレマーケット取引で動いている他の銘柄です。
<h3 class="wp-block-heading">株価最大上昇</h3>
<ul>
<li>本日のプレマーケット取引でGolden Heaven Group Holdings Ltd（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>）の株は0.3049ドル（70.3%高）に上昇しました。</li>
<li>本日のプレマーケット取引でWANG＆amp;LEE GROUP, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>）の株は0.8760ドル（43.1%高）に上昇し、火曜日には16%上昇していました。</li>
<li>本日のプレマーケット取引でSurf Air Mobility Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>）の株は0.3860ドル（38%高）となりました。 Surf Air MobilityはブラジルのCessna Caravanを運営するAsta社に電動パワートレインを供給する合意を締結しました。</li>
<li>本日のプレマーケット取引でBeamr Imaging Ltd.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>）の株は5.64ドル（28.2%高）に上昇しました。 Beamrは、同社のクラウドソリューションが現在、Oracle Cloud Marketplaceで利用可能であると述べています。</li>
<li>本日のプレマーケット取引でCastellum, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>）の株は0.2410ドル（24.9%高）に上昇しました。</li>
<li>火曜日にTrianが同社に出資しているとの報告に続き、本日のプレマーケット取引でRentokil Initial plc（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>）の株は30.01ドル（11.5%高）に上昇しています。</li>
<li>本日のプレマーケット取引でThe Aaron&#8217;s Company, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>）の株は8.88ドル（10.9%高）に上昇しました。</li>
<li>本日のプレマーケット取引でMereo BioPharma Group plc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>）の株は3.90ドル（10.8%高）に上昇しました。UltragenyxとMereoは、第2/3部分の第2相Orbit試験の14か月の結果を発表しました。</li>
<li>本日のプレマーケット取引でAyro, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>）の株は0.8991ドル（9.6%高）に上昇しました。</li>
</ul>
<h3 class="wp-block-heading">株価最大下落</h3>
<ul>
<li>ナスダックは、ThermoGenesis Holdings, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>）の株がプレマーケット取引で49.8%下落し0.2691ドルに低下したことを受け、同社のリスティング維持要請を拒否しました。同社の株は2024年6月17日の取引開始時に取引が停止されます。</li>
<li>火曜日には4%下落していたことを受け、本日のプレマーケット取引でClene Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>）の株は0.31ドル（24.7%下落）に低下しました。</li>
<li>本日のプレマーケット取引でTonix Pharmaceuticals Holding Corp（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>）の株は1.61ドル（24.4%下落）に下落しました。同社は株式の公開募集を発表しました。</li>
<li>火曜日の取引で17%上昇した後、本日のプレマーケット取引でKWESST Micro Systems Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>）の株は0.7965ドル（21.9%下落）に下落しました。KWESST Micro Systemsは最近、ソフトウェア開発サービスに関するThales Canada社から最大4800万カナダドル相当のサブ契約を受けました。</li>
<li>火曜日には5%上昇していたことを受け、本日のプレマーケット取引でShiftPixy, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>）の株は1.32ドル（14.3%下落）に低下しました。</li>
<li>火曜日には5%下落していたことを受け、本日のプレマーケット取引でOblong, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>）の株は0.1723ドル（14.2%下落）に低下しました。Obglongは最近、Dwellwell Analyticsを取得するための拘束力のない意向書に署名しました。</li>
<li>火曜日には混合の四半期決算を発表し、本日のプレマーケット取引でPetMed Express, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>）の株は4.06ドル（13.8%下落）に低下しました。同社は、四半期決算において難しいマクロ環境と業界の動向が結果に悪影響を及ぼしたと述べています。</li>
<li>火曜日には13%上昇した後、本日のプレマーケット取引でmF International Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>）の株は0.99ドル（13%下落）に低下しました。</li>
<li>火曜日には32%上昇した後、本日のプレマーケット取引でCalidi Biotherapeutics, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>）の株は0.2370ドル（12.2%下落）に低下しました。Calidi Biotherapeuticsは最近、肺がんおよび転移性固形腫瘍のためのCalidiのRTNovaウイロセラピーを進めるためにSIGA Technologies社と協力することを発表しました。</li>
<li>火曜日に23%下落した後、本日のプレマーケット取引でBig Tree Cloud Holdings Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>）の株は2.45ドル（11.9%下落）に低下しました。Big Tree Cloudは最近、Plutonian Acquisition Corp とのビジネスコンビネーションを完了したことを発表しました。</li>
</ul>

Comments

Calidi Biotherapeutics

ニュース

最新ニュース Calidi Biotherapeutics (AMEX:CLDI) 株価情報

水曜日, 6 12, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル